Evidence map›Paper›PMID 39390256›Full record

ArticleOncogene2024

m

Yujiao Liu, Jia Li, Jie Xu, Yingfei Long, Yuan Wang, Xiaoyi Liu, Junchi Hu, Qinglv Wei, Qingya Luo, Fatao Luo and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. RNA modifications and cancer ferroptosis.Cancer cell international · 2026
    Review
  12. Review
  13. The NAT10/acCell communication and signaling : CCS · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. MJournal of ovarian research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yujiao Liu *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Jia Li *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Jie Xu *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Yingfei LongDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Yuan WangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Xiaoyi LiuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Junchi HuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Qinglv WeiDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Qingya LuoDepartment of Pathology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Fatao LuoDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Fengjiang QinDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Qihua YiDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Yu YangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Yongjun DangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Jing XuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Tao LiuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China. anti1988@163.com.ORCID 0000-0001-9025-612X
Ping YiDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China. yiping@cqmu.edu.cn.ORCID 0000-0001-7111-6308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA epigenetic modifications have been implicated in cancer progression. However, the interplay between distinct RNA modifications and its role in cancer metabolism remain largely unexplored. Our study demonstrates that N-acetyltransferase 10 (NAT10) is notably upregulated in ovarian cancer (OC), correlating with poor patient prognosis. IGF2BP1 enhances the translation of NAT10 mRNA in an m

Indexed as

CarcinogenesisFatty AcidsFerroptosisOvarian NeoplasmsAcetylationAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceN-Terminal Acetyltransferase EN-Terminal AcetyltransferasesProtein BiosynthesisRNA, MessengerVidarabineFatty AcidsfludarabineNAT10 protein, humanN-Terminal Acetyltransferase EN-Terminal AcetyltransferasesRNA, MessengerVidarabine

Identifiers

PMID39390256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.